Vyome Holdings' ReShape Lifesciences Has Received A Notice Of Allowance For A U.S. Patent Titled "VAGUS NERVE NEUROMODULATION FOR THE TREATMENT OF THE HYPOGLYCEMIC STATE".
https://patentcenter.uspto.gov/applications/18702356/ifw/docs
Stocks · News reference
Vyome Holdings, Inc. announced that its Scientific Co-Founder and Director, Dr. Shiladitya Sengupta, has been promoted to Professor of Medicine at Harvard Medical School.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
https://patentcenter.uspto.gov/applications/18702356/ifw/docs
Finance executive with more than 25 years of experience brings extensive expertise in public company financial management, SEC reporting, financial operations, and governanceVyome Holdings, Inc. (NASDAQ:HIND)
Chardan Capital analyst Keay Nakae initiates coverage on Vyome Holdings (NASDAQ:HIND) with a Buy rating and announces Price Target of $3.5.
On August 27, 2026, the board of directors (the "Board") of Vyome Holdings, Inc. (the "Company") appointed Jerry Leonard as the Company’s Chief Financial Officer. In connection with Mr. Leonard’s
Filed: 2026-08-28 AccNo: 0001213900-26-095093 Size: 267 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out